JNJ-78934804 vs SOR102

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanisms: IL-23 p19 · TNF-alpha · full Ulcerative Colitis pipeline

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Ulcerative ColitisCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT07577856 (registry estimate)

No aligned efficacy figure on record for this race.

SOR102

Developed by Sorriso Pharmaceuticals

Phase 1 in Ulcerative ColitisBiologic (oral dual TNFα/IL-23(p19) inhibitor)
Weak signal

NCT06080048 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Treatment Emergent Adverse Events following oral dosing". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Treatment Emergent Adverse Events following oral dosing (Up to 6 weeks in Part 3 or at the time of study discontinuation): First-in-human phase 1. Part 1 (healthy participants): treatment-emergent adverse events in 3/24 (13%) receiving SOR102 versus 2/8 (25%) receiving placebo. Part 2: no treatment-emergent adverse events in the 10 participants receiving twice-daily SOR102. Part 3 (ulcerative colitis patients): at least one adverse event in 7/16 (44%) treated with SOR102 and 3/6 (50%) receiving placebo. Rates of clinical response ranged from 29% to 67%, depending on the definition applied.

Result source: NCT06080048

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJNJ-78934804SOR102
Clinical remission (induction)—Trial running · NCT07577856—Not reported
Clinical remission (maintenance)—Trial running · NCT07577856—Not reported
Clinical response (induction)—Trial running · NCT07577856—Not reported
Endoscopic improvement (induction)—Trial running · NCT07577856—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT07577856—Not reported

Clinical remission (induction)

JNJ-78934804
—Trial running · NCT07577856
SOR102
—Not reported

Clinical remission (maintenance)

JNJ-78934804
—Trial running · NCT07577856
SOR102
—Not reported

Clinical response (induction)

JNJ-78934804
—Trial running · NCT07577856
SOR102
—Not reported

Endoscopic improvement (induction)

JNJ-78934804
—Trial running · NCT07577856
SOR102
—Not reported

Corticosteroid-free remission (maintenance)

JNJ-78934804
—Trial running · NCT07577856
SOR102
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.

SOR102: no structured comparison results are available for Ulcerative Colitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JNJ-78934804's landscape · SOR102's landscape